Veracyte: From Clinical Evidence Flywheel to a Scalable Cash-Flow Engine
Veracyte has spent years building clinical evidence for Afirma, Percepta and Envisia. That investment is paying off in predictable revenue, margin expansion and real free cash flow. With $155m of free cash flow, an asset-light balance sheet and ongoing cost rationalization, the stock is a set-up for a mid-term move higher if volume and payer moment…